Cellumed Achieves Record Monthly Performance in Bone Graft Materials... Anticipates Improved Results in Second Half

Cellumed, a subsidiary of InskoBi and a specialized manufacturer of bio-medical devices, announced on June 30 that its bone graft material products achieved the highest monthly performance on record. Following last month’s record-high production volume, the company’s strategy of expanding supply and diversifying distribution channels is now showing tangible results.

The company explained that, in particular, the increase in orders from domestic medical institutions, along with the expansion of exports, served as key drivers for achieving the highest monthly sales. It is also noteworthy that, despite the expanded supply, demand has been able to absorb it stably. As production volume increases and sales follow rapidly, inventory turnover has also risen, and the company expects this to lead to improved financial stability.

Cellumed primarily produces the orthopedic bone graft material ‘Rafugen DBM (Demineralized Bone Matrix)’ and the dental bone graft material ‘Rafugen Dental.’ As both products are used directly in the human body, the company has been strengthening its competitiveness not only in the domestic market but also globally by introducing automated facilities to minimize human error and implementing a strict quality control system.

In addition, focusing on its ‘Production Process TFT,’ the company is concentrating on enhancing its manufacturing capabilities by expanding production capacity (CAPA), standardizing production, and improving user convenience and safety in medical settings.

Based on these results, the company plans to accelerate sales growth in the second half of the year. With demand for bone graft materials continuing to rise, Cellumed aims to further expand supply through major domestic hospitals and dental networks, as well as intensify its efforts to penetrate overseas markets.

A Cellumed representative stated, “This record-high monthly performance is the result of strengthening production capabilities and diversifying distribution strategies,” adding, “In the second half of the year, we will proactively respond to growing demand in both domestic and international markets, further expand supply, and thereby accelerate our sales growth.”